

Therapeutic Drug Monitoring

Technologies, Companies & Markets

By

**Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland**

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

His important books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Drug-induced Neurological Disorders", 3rd ed (Hogrefe 2011), "Applications of Biotechnology in Cardiovascular Disorders" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

December 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	10
1. Introduction	12
Definitions	12
Historical Landmarks in the development of TDM	12
Pharmacology relevant to TDM	13
Pharmacokinetics	13
Pharmacodynamics	14
Pharmacogenetics	14
Pharmacogenomics	14
Pharmacoproteomics	14
Drug receptors	14
Protein binding	15
Therapeutic range of a drug.....	15
Variables that affect TDM.....	15
Indications for TDM	16
Multidisciplinary nature of TDM	17
Role of TDM in personalized medicine.....	18
2. Technologies for TDM	20
Introduction	20
Sample preparation	20
Proteomic technologies	20
Mass spectrometry	20
<i>Liquid chromatography MS.....</i>	<i>20</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry</i>	<i>21</i>
<i>Combining capillary electrophoresis with MS.....</i>	<i>21</i>
<i>Gas-liquid chromatography</i>	<i>21</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>22</i>
<i>New trends in sample preparation</i>	<i>22</i>
<i>Pressure Cycling Technology</i>	<i>22</i>
Desorption electrospray ionization imaging	23
High Performance Liquid Chromatography (HPLC)	23
<i>Ultra performance LC</i>	<i>23</i>
Application of HPLC and MS for separation of drug molecules	24
TDM using dry blood spots	25
<i>Analysis of dried blood spots for drugs using DESI</i>	<i>25</i>
<i>Quantitative analysis of drugs in dried blood spot by paper spray MS</i>	<i>25</i>
Immunoassays	26
Enzyme-linked immunosorbent assay	26
Cloned Enzyme Donor Immunoassay.....	26
Enzyme Multiplied Immunoassay Technique	27
Fluorescence Polarization Immunoassay	27
Particle Enhanced Turbidimetric Inhibition Immunoassay	27
Radioimmunometric assays	28
Biosensors	28
Biochips & Microarrays	29
Introduction	29
Microchip capillary electrophoresis	29
Phototransistor biochip biosensor.....	30
Microchip-based fluorescence polarization immunoassay for TDM.....	30
Cellular microarrays	30
Microfluidics for TDM	30
<i>Lab-on-a-chip.....</i>	<i>31</i>
<i>Micronics' microfluidic technology.....</i>	<i>31</i>
<i>Rheonix CARD technology</i>	<i>31</i>
<i>Nano-interface in a microfluidic chip.....</i>	<i>32</i>
<i>Levitation of nanofluidic drops with physical forces.....</i>	<i>32</i>
Nanoarrays	32
Nanobiotechnology	33
NanoDx™	33
Biomarkers	33
Applications of biomarkers in drug safety studies	34
Genomic technologies for toxicology biomarkers	35
Proteomic technologies for toxicology biomarkers	35
Metabonomic technologies for toxicology biomarkers.....	35
Integration of genomic and metabonomic data to develop toxicity biomarkers.....	36

Toxicology studies based on biomarkers	36
<i>Biomarkers of hepatotoxicity</i>	37
<i>Biomarkers of nephrotoxicity</i>	38
<i>Cardiotoxicity</i>	39
<i>Neurotoxicity</i>	40
Biomarkers in clinical trials	40
Molecular diagnostics	41
Novel technologies for TDM at point-of-care	41
NanoEye	42
Nanobiosensors	43
3. Drug Monitoring Instruments	44
Introduction	44
Description of important instruments	44
Abbott instruments	44
ARCHITECT c16000	44
ARCHITECT c4000	45
ARCHITECT c8000	45
ARCHITECT ci16200 Integrated System	45
ARCHITECT ci4100 Integrated System	46
ARCHITECT ci8200 integrated with the ARCHITECT i2000SR	46
ARCHITECT i1000SR	46
ARCHITECT i4000SR	47
AxSYM	47
Agilent's 6400 Series Triple Quadrupole LC/MS	48
Alfa Wassermann's ACE Alera	48
AMS Diagnostics' LIASYS	48
Beckman Coulter instruments	48
Beckman Coulter Unicel Series	48
AU5800 automated chemistry systems	49
AU480	49
Binding Site ESP600	50
bioMerieux Mini Vidas	50
Carolina BioLis 24i	50
Chromsystems' HPLC instruments	51
Grifols Triturus	51
ABX Pentra 400	51
Medica EasyRA	52
Nova Biomedical Critical Care Xpress	52
Ortho Clinical Diagnostics' VITROS® family of systems	52
Immunodiagnostic systems	53
Randox instruments	53
Randox RX Imola	53
Roche instruments	54
Cobas® 8000	54
COBAS INTEGRA® Systems	54
SCIEX instruments	54
SCIEX LC/MS/MS	54
Siemens instruments	55
ADVIA 1200	55
ADVIA Centaur XP immunoassay system	55
CLINITEK® AUWi System	55
Dimension® Xpand® Plus Integrated Chemistry System	55
EMIT® II Plus Syva®	56
Viva® Drug Testing Systems	56
Thermo Scientific instruments	56
Indiko	56
Tosoh AIA-Series	57
4. Applications of TDM	58
Introduction	58
Pharmaceutical research and drug development	58
Clinical trials	58
Computerized clinical decision support systems for TDM and dosing	58
Medication-related interferences with measurements of catecholamines	59
Polymorphisms of genes affecting drug metabolism	59
TDM for drug safety	59
TDM in special groups	60
The aged	60
Children	60
Pregnancy	60

TDM of prophylactic therapy	61
Monitoring of vitamin D levels	61
Monitoring of RBC folic acid levels during pregnancy	61
Applications according to various conditions	61
Anesthesia and critical care	61
<i>Optimizing antimicrobial dosing for critically ill patients</i>	<i>62</i>
<i>TDM monitoring of thiopental continuous infusion in critical care</i>	<i>62</i>
<i>Role of TDM in critical care cardiac patients</i>	<i>63</i>
Cancer.....	63
Epilepsy.....	64
<i>Personalized approach to use of AEDs.....</i>	<i>64</i>
Infections	65
<i>Virus infections.....</i>	<i>65</i>
<i>Fungal infections.....</i>	<i>65</i>
Pain management	66
<i>Role of TDM in pain management.....</i>	<i>66</i>
<i>Monitoring of analgesic drugs in urine samples</i>	<i>66</i>
<i>AEDs as analgesics.....</i>	<i>67</i>
<i>Triptans for migraine.....</i>	<i>67</i>
Psychiatric disorders.....	67
<i>Guidelines for use of TDM in psychiatric patients.....</i>	<i>67</i>
<i>TDM of psychotropic drugs</i>	<i>69</i>
Emergency toxicology.....	69
Future of TDM	69
5. Drugs Requiring Monitoring	72
Introduction	72
Anticoagulants.....	73
<i>Dabigatran.....</i>	<i>74</i>
Analgesics	74
Monitoring of opioid use.....	74
<i>TDM of morphine</i>	<i>75</i>
<i>TDM of oxycodone.....</i>	<i>75</i>
<i>TDM of codeine.....</i>	<i>76</i>
Antiepileptics.....	76
Carbamazepine.....	77
<i>TDM of carbamazepine</i>	<i>77</i>
Gabapentin	78
Lacosamide.....	78
Lamotrigine.....	78
<i>TDM of lamotrigine.....</i>	<i>79</i>
Levetiracetam	79
<i>TDM of levetiracetam</i>	<i>80</i>
Phenobarbital	80
<i>TDM of phenobarbital</i>	<i>81</i>
Phenytoin	81
<i>TDM of phenytoin.....</i>	<i>81</i>
Primidone	82
<i>TDM of primidone.....</i>	<i>82</i>
Topiramate	83
<i>TDM of topiramate</i>	<i>83</i>
Valproic acid.....	83
<i>TDM of valproic acid</i>	<i>84</i>
TDM of multiple antiepileptic drugs in plasma/serum	84
Antiinflammatory agents	86
Infliximab	86
Antimicrobials.....	86
Antibiotics.....	87
<i>Amikacin.....</i>	<i>87</i>
<i>Anti-tuberculosis drugs.....</i>	<i>87</i>
<i>Chloramphenicol.....</i>	<i>87</i>
<i>Gentamicin.....</i>	<i>88</i>
<i>Tobramycin.....</i>	<i>88</i>
<i>Vancomycin.....</i>	<i>88</i>
<i>Norvancomycin.....</i>	<i>89</i>
Antiviral agents	89
<i>Anti-HIV drugs.....</i>	<i>89</i>
Antifungal agents.....	89
<i>Voriconazole.....</i>	<i>89</i>
Antidepressants.....	90
TDM of selective serotonin reuptake inhibitors	91

<i>Citalopram</i>	91
Antipsychotics	91
Aripiprazole.....	92
Clozapine.....	92
Quetiapine	93
Risperidone.....	93
TDM of AEDs in psychiatric disorders	94
TDM of multiple drugs in psychiatry	94
Bronchodilators	94
Theophylline.....	94
Cardiovascular drugs	95
Antiarrhythmic drugs.....	95
Antihypertensive drugs	95
<i>β-blockers</i>	95
Cardiotonic drugs.....	95
<i>Digoxin</i>	95
TDM of statins for hypercholesterolemia	96
Chemotherapy for cancer	96
TDM of 5-FU.....	96
TDM of imitanzib	97
TDM of Methotrexate	97
TDM of paclitaxel	97
Drugs used for treatment of Alzheimer disease	97
Donepezil.....	98
Galantamine.....	98
Memantine	98
Drugs used for treatment of Parkinson disease	99
Monitoring of levodopa and carbidopa therapy.....	99
Catechol-O-methyltransferase inhibitors	100
Drugs for treatment of attention-deficit hyperactivity disorder	100
Atomoxetine.....	100
Methylphenidate	101
Hypnotic-sedative drugs	101
Benzodiazepines	101
Propofol.....	102
Immunosuppressive drugs	102
Immunosuppressants used for the treatment of various diseases	102
<i>Azathioprine</i>	102
<i>Hydroxychloroquine for patients with systemic lupus erythematosus</i>	103
<i>Methotrexate for rheumatoid arthritis</i>	103
<i>Mycophenolic acid for the treatment of lupus nephritis</i>	103
Immunosuppressants used for prevention of organ rejection in transplantation	103
TDM of Tacrolimus in transplantation	104
TDM of cyclosporine A in transplantation	105
Monitoring of immunosuppression with mycophenolate mofetil	105
Steroids	105
Prednisone	105
Miscellaneous drugs	106
Nimodipine.....	106
Sildenafil	107
6. Monitoring of Biological Therapies	108
Introduction	108
Cell therapy	108
In vivo tracking of cells.....	108
<i>Molecular imaging for tracking cells</i>	108
<i>MRI technologies for tracking cells</i>	109
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	110
<i>Visualization of gene expression in vivo by MRI</i>	110
Gene therapy	111
Application of molecular diagnostic methods in gene therapy	111
Use of PCR to study biodistribution of gene therapy vector.....	111
PCR for verification of the transcription of DNA	112
In situ PCR for direct quantification of gene transfer into cells	112
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	112
Confirmation of viral vector integration	112
Monitoring of gene expression	112
<i>Monitoring of gene expression by green fluorescent protein</i>	113
<i>Monitoring in vivo gene expression by molecular imaging</i>	113
Monoclonal antibodies	114
Natalizumab	114

7. Monitoring of Drug Abuse	116
Introduction	116
Tests used for detection of drug abuse	117
Forensic applications of detection of illicit drugs in fingerprints by MALDI MS	117
MS for doping control	118
Randox assays for DoA	118
Drugs of Abuse Array V	118
Urine drug testing	119
TDM of drugs for treatment of substance abuse-related disorders	119
Drug testing to monitor treatment of drug abuse	119
Minimum requirement for drug testing in patients	120
Analgesic abuse	120
Fentanyl abuse	120
B-blockers as doping agents	121
Detection of β -blockers in urine	121
Chronic alcohol abuse	121
Cocaine	122
CEDIA for cocaine in human serum	122
Detection of cocaine molecules by nanoparticle-labeled aptasensors	122
Infrared spectroscopy for detection of cocaine in saliva	122
Marijuana	123
Use of marijuana and synthetic cannabinoids	123
Detection of cannabinoids	124
<i>ELISA for detection of synthetic cannabinoids</i>	124
Drug abuse for performance enhancement in sports	124
Historical aspects of drug abuse in sports	124
Drugs used by athletes for performance enhancement	125
Techniques used for detection of drug abuse by athletes	127
<i>Mass spectrometry for detection of peptide hormones</i>	127
<i>miRNAs for the detection of erythropoiesis-stimulating agents</i>	127
<i>Detection of anabolic steroids</i>	127
Body fluids and tissues used for detection of drug abuse in sports	128
<i>Urine drug testing</i>	128
<i>Spray (sweat) drug test kits</i>	128
<i>Hair drug testing</i>	128
Gene doping in sports	128
<i>Gene transfer methods used for enhancing physical performance</i>	129
<i>Misuse of cell therapy in sport</i>	130
<i>Challenges of detecting genetic manipulations in athletes</i>	131
Drug abuse testing in race horses	131
Limitations and future	132
Role of pharmaceutical industry in anti-doping testing	133
8. Markets for TDM	134
Introduction	134
Methods for market estimation and future forecasts	134
Global markets for TDM tests	134
Global markets for TDM according to technologies	135
Global TDM markets according to drug categories	135
<i>Agents used for treatment of Alzheimer disease</i>	136
<i>Analgesics</i>	136
<i>Anticancer agents</i>	136
<i>Anticoagulants</i>	136
<i>Antidepressants</i>	137
<i>Antiepileptics</i>	137
<i>Antimicrobials</i>	137
<i>Antipsychotics</i>	137
<i>Biological therapies</i>	137
<i>Bronchodilators</i>	137
<i>Cardiovascular drugs</i>	138
<i>Corticosteroids/antihistaminics/antiinflammatory agents</i>	138
<i>Hypnotic-sedatives</i>	138
<i>Immunosuppressants</i>	138
<i>Parkinson disease drugs</i>	138
Breakdown of global markets according to point of application of tests	138
Markets for TDM and DoA testing equipment	139
Geographical distribution of markets for TDM tests	139
Drivers for growth of TDM markets	140
Markets for DoA testing	141
Unmet needs in TDM	141
Cost-benefit studies	142

Simplifying assays and reducing time and cost	143
Strategies for developing markets	143
Physician education	144
Supporting research on TDM	144
Biomarker patents for drug monitoring	144
9. Companies	146
Profiles of companies.....	146
Collaborations.....	193
10. References.....	194

Tables

Table 1-1: Historical landmarks in the development of therapeutic drug monitoring	12
Table 4-1: Psychotropic drugs requiring TDM	68
Table 5-1: Drugs requiring TDM.....	72
Table 5-2: Indications and therapeutic ranges of various AEDs	77
Table 6-1: Molecular imaging methods for tracking cells in vivo	109
Table 6-2: Applications of molecular diagnostics in gene therapy	111
Table 7-1: Commonly tested drugs of abuse and recreational drugs	116
Table 7-2: Testing and confirmation cutoff concentrations/detection times for DoA	120
Table 7-3: Historical landmarks of drug abuse in sports	125
Table 7-4: Drugs used by athletes for performance enhancement	125
Table 7-5: Genes that may be used for performance enhancement	129
Table 8-1: Global markets for TDM according to technologies from 2016-2026	135
Table 8-2: Global markets for TDM according to drug categories 2016-2026	135
Table 8-3: Global markets for TDM according to point of application 2016-2026	139
Table 8-4: Markets for TDM and DoA testing equipment 2016-2026	139
Table 8-5: Geographical distribution of markets for TDM tests 2016-2026	140
Table 8-6: Drivers for growth of TDM markets	140
Table 8-7: Global markets for DoA testing 2016-2026	141
Table 9-1: Major players in therapeutic drug monitoring.....	146
Table 9-2: Drugs for which monitoring and detection tests are provided by LabCorp	167
Table 9-3: Collaborations of companies involved in TDM	193

Figures

Figure 1-1: Therapeutic window of a drug	15
Figure 1-2: Therapeutic range of a drug	15
Figure 1-3: Flow chart of TDM	17
Figure 1-4: Interrelationships of TDM	17
Figure 2-1: Separation of structurally similar drug molecules by HPLC.....	24
Figure 2-2: Determination of the identity of a target substance by mass spectrometry	24
Figure 2-3: Basic principle of a biosensor.....	29
Figure 8-1: Unmet needs in TDM	142
Figure 8-2: Metabolism of azathioprine and biomarkers for TDM	145